An anonymous benefactor has transferred a whopping $4 million into researching the therapeutic effects of MDMA on PTSD sufferers.
The anonymous donor has reportedly given The Multidisciplinary Association for Psychedelic Studies (MAPS) an ultimatum — giving up the $4 million, so long as MAPS raises another $4 million themselves by March 10th.
“PTSD is a severe condition that affects everyone from sexual assault survivors to military veterans” reads a statement from the donor. “MDMA-assisted psychotherapy has shown great promise. We’re offering the matching grant because we think the psychedelic and cryptocurrency communities can work together to finish funding Phase III clinical trials.”
Last year, the FDA pushed MDMA to Phase II testing and identifying the drug as “breakthrough” in PTSD treatment, effectively speeding up research that utilizes the chemical in its trials.
An estimated 7.8 percent of Americans will experience PTSD — Post Traumatic Stress Disorder — at some point in their lives, with women (10.4%) twice as likely as men (5%) to develop PTSD.